Apotea AB/Skr APOTEA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Apotea AB
Apotea AB is a Swedish online pharmacy specializing in the sale of pharmaceutical products and related health items. As an e-commerce platform, Apotea offers a wide range of over-the-counter medications, prescription drugs, supplements, and wellness products. The company has established itself as a prominent digital player in the pharmaceutical retail sector in Sweden, leveraging an efficient distribution system for fast delivery services. Headquartered in Stockholm, Apotea emphasizes sustainable business practices, such as environmentally friendly packaging and delivery methods. Its strategic use of digital infrastructure enables cost-effective operations and competitive pricing, contributing to its strong market position in the e-commerce space for healthcare products in Sweden.
- Ticker
- Skr APOTEA
- Sector
- Consumer Essentials
- Primary listing
- XSTO
- Employees
- 736
- Headquarters
- Stockholm, Sweden
- Website
- www.apotea.se
Apotea AB Metrics
BasicAdvanced
kr 9.6B
39.07
kr 2.36
-
kr 0.60
0.65%
Price and volume
Market cap
kr 9.6B
52-week high
kr 94.50
52-week low
kr 54.42
Average daily volume
259K
Dividend rate
kr 0.60
Financial strength
Current ratio
1.399
Quick ratio
0.555
Long term debt to equity
0.226
Total debt to equity
0.29
Dividend payout ratio (TTM)
25.40%
Interest coverage (TTM)
25.62%
Profitability
EBITDA (TTM)
452.1
Gross margin (TTM)
19.85%
Net profit margin (TTM)
3.24%
Operating margin (TTM)
4.19%
Effective tax rate (TTM)
21.81%
Revenue per employee (TTM)
kr 10,310,000
Management effectiveness
Return on assets (TTM)
9.45%
Return on equity (TTM)
27.83%
Valuation
Price to earnings (TTM)
39.068
Price to revenue (TTM)
1.264
Price to book
10.13
Price to tangible book (TTM)
10.63
Price to free cash flow (TTM)
63.672
Free cash flow yield (TTM)
1.57%
Free cash flow per share (TTM)
1.448
Dividend yield (TTM)
0.65%
Forward dividend yield
0.65%
Growth
Revenue change (TTM)
9.38%
Earnings per share change (TTM)
-1.75%
What the Analysts think about Apotea AB
Analyst ratings (Buy, Hold, Sell) for Apotea AB stock.
Analyst projections of the future price of Apotea AB stock.
Bulls say / Bears say
Second-quarter revenue rose 10.9% to SEK 2.03bn and EBIT increased to SEK 104.4m from SEK 93.1m, showing that Apotea is growing while generating higher operating profit. (Apotea)
Varberg handled more of the larger orders as daily output topped 30,000, against automation capacity of 50,000 orders. Higher use of the site is already improving cost efficiency and could support further operating leverage. (StockAnalysis)
Apotea expanded same-day delivery to another million Swedes, taking potential coverage to 3.7 million residents. Faster delivery may help it attract and retain customers as its service reaches more of the country. (MFN.se)
Operating cash flow fell to SEK 76.8m from SEK 165.3m year on year in the second quarter. The company attributed the drop partly to stock build-up at Varberg, and inventory exceeded SEK 850m at quarter-end. (Apotea)
A review of pharmacy reimbursement could introduce different margins for online and physical sales, potentially reducing Apotea’s gross profit on prescriptions. The regulated nature of this income leaves the company exposed to policy changes it cannot readily offset. (EFN)
SEB says the shares need a clearer acceleration in growth to offer further upside. If sales momentum does not strengthen, investors may question whether the current share price is justified by the earnings outlook. (Börsvärlden)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
Apotea AB Financial Performance
Revenues and expenses
Apotea AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Apotea AB
Fund name | Fund size | Skr APOTEA weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.03% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.03% |
iShares Digitalisation$DGTL | $761M | 0.03% |
iShares Digitalisation£DGIT | $813M | 0.03% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.